EUVIMEDEUVIMED entdecken
Vergleichsstudie

Clinical effect of roxadustat vs. erythropoietin in non-dialysis CKD with diabetes: a single center propensity score matching analysis

Chen Jin, Yan Ren, Minmin Wang, Xiao Hu, Yiwei Shang, Yiwen Li, Bin Zhu, Qiang He, Lina Shao

International Urology and Nephrology · 2024

DOI: 10.1007/s11255-024-03983-0 ↗

Kurz gefasst

Vergleichsstudie in der Zeitschrift International Urology and Nephrology, 2024. Verfasst von Chen Jin und 8 weiteren Autor:innen. Beteiligte Einrichtung: Bengbu Medical College, Bengbu, China. Hauptthemen laut MEDLINE: Propensity Score, Erythropoietin, Renal Insufficiency, Chronic, Anemia. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 36 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

PURPOSE: Renal anemia is a common complication of chronic kidney disease. Currently, recombinant human erythropoietin and roxadustat are the main treatments. In China, diabetic kidney disease is the primary cause of chronic kidney disease. However, high-quality evidence on the efficacy of roxadustat in patients with non-dialysis-dependent chronic kidney disease and diabetes mellitus is scarce. This study aimed to assess the clinical effect of roxadustat in such patients. METHODS: Patients with non-dialysis-dependent anemia and diabetes mellitus who received roxadustat or recombinant human erythropoietin for ≥ 4 weeks were enrolled. We compared baseline characteristics, including age, gender, hypertension, and hemoglobin level, and then employed a 1:3 ratio propensity score matching. The primary efficacy outcomes were changes in hemoglobin levels. After propensity score matching, 212 patients were analyzed, including the roxadustat (n = 53) and recombinant human erythropoietin (n = 159) groups. Baseline characteristics were comparable, including hemoglobin level, estimated glomerular filtration rate, and glycated hemoglobin A1c (p > 0.05). RESULTS: After 4, 12, and 24 weeks of treatment, the median hemoglobin levels in the roxadustat group were 97.5 g/L, 104 g/L, and 106.5 g/L, respectively, significantly surpassing the corresponding levels in the recombinant human erythropoietin group at 91 g/L, 94.5 g/L, and 94.5 g/L (p = 0.002, p = 0.025, p = 0.006, respectively). Additionally, subgroup analysis demonstrated better treatment efficacy of roxadustat patients with elevated high-sensitivity C-reactive protein and low albumin levels. CONCLUSION: In Chinese patients with anemia and diabetes not on dialysis, roxadustat efficiently and rapidly improved and maintained hemoglobin levels unaffected by elevated high-sensitivity C-reactive protein and low albumin levels.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Propensity ScoreErythropoietinRenal Insufficiency, ChronicAnemiaIsoquinolinesHumansMaleFemaleMiddle AgedAgedGlycineRecombinant ProteinsTreatment OutcomeHemoglobinsRetrospective StudiesDiabetes Mellitus

Stichwörter der Autor:innen

Chronic kidney diseaseDiabetes mellitusHemoglobin levelsRecombinant human erythropoietinRenal anemiaRoxadustat

Substanzen

ErythropoietinroxadustatIsoquinolinesGlycineRecombinant ProteinsHemoglobins

Autor:innen und Institutionen

  • Bengbu Medical College, Bengbu, China.
  • Urology and Nephrology Center, Department of Nephrology, Zhejiang Provincial People's Hospital (Affiliated People's Hospital, Hangzhou Medical College), Hangzhou, 310014, China.
  • Bengbu Medical College, Bengbu, China. qianghe1973@126.com.
  • Urology and Nephrology Center, Department of Nephrology, Zhejiang Provincial People's Hospital (Affiliated People's Hospital, Hangzhou Medical College), Hangzhou, 310014, China. qianghe1973@126.com.
  • Department of Nephrology, The First Affiliated Hospital of Zhejiang Chinese Medical University (Zhejiang Provincial Hospital of Traditional Chinese Medicine), Hangzhou, 310006, China. qianghe1973@126.com.
  • Urology and Nephrology Center, Department of Nephrology, Zhejiang Provincial People's Hospital (Affiliated People's Hospital, Hangzhou Medical College), Hangzhou, 310014, China. shaolina@hmc.edu.cn.

Zitieren

APA

Jin, C., Ren, Y., Wang, M., Hu, X., Shang, Y., Li, Y., Zhu, B., He, Q., & Shao, L. (2024). Clinical effect of roxadustat vs. erythropoietin in non-dialysis CKD with diabetes: a single center propensity score matching analysis. International Urology and Nephrology. https://doi.org/10.1007/s11255-024-03983-0

Vancouver

Jin C, Ren Y, Wang M, Hu X, Shang Y, Li Y, et al. Clinical effect of roxadustat vs. erythropoietin in non-dialysis CKD with diabetes: a single center propensity score matching analysis. International Urology and Nephrology. 2024. doi:10.1007/s11255-024-03983-0

BibTeX
@article{Jin2024,
  author = {Jin, Chen and Ren, Yan and Wang, Minmin and Hu, Xiao and Shang, Yiwei and Li, Yiwen and Zhu, Bin and He, Qiang and Shao, Lina},
  title = {Clinical effect of roxadustat vs. erythropoietin in non-dialysis CKD with diabetes: a single center propensity score matching analysis},
  journal = {International Urology and Nephrology},
  year = {2024},
  doi = {10.1007/s11255-024-03983-0}
}
Kostenlos starten →